Article excerpt
There are moments in science when something small and elusive suddenly becomes attainable, when a molecule trapped in the fine print of research papers becomes the centerpiece of an entirely new chapter in health. That is what happened when eXoZymes turned its attention to plant-derived N-trans-caffeoyltyramine (NCT), an investigational compound with the potential to change how the world treats chronic metabolic and inflammatory diseases.
“The beauty of leading with NCT,” said Damien Perriman, eXoZymes’ Chief Commercial Officer, “is that we’ve taken something nature only whispers about and figured out how to make it into something we can actually use, because we can provide it at scale.”
Click here to read the full article
